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Abstract
Objectives: The objective of this study was to assess the existing theoretical and empirical literature examining the link between “local 
production” of pharmaceuticals and medical devices and increased local access to these products. Our preliminary hypothesis is that 
studies showing a robust relationship between local production and access to medical products are sparse, at best.
Methods: An extensive literature search was conducted using a wide variety of databases and search terms intending to capture as 
many different aspects of this issue as possible. The results of the search were reviewed and categorized according to their relevance 
to the research question. The literature was also reviewed to determine the rigor used to examine the effects of local production and 
what implications these experiences hold for other developing countries.
Results: Literature addressing the benefits of local production and the link between it and access to medical products is sparse, mainly 
descriptive and lacking empirical evidence. Of the literature we reviewed that addressed comparative economics and strategic planning 
of multinational and domestic firms, there are few dealing with emerging markets and lower-middle income countries and even fewer 
that compare local biomedical producers with multinational corporations in terms of a reasonable metric. What comparisons exist 
mainly relate to prices of local versus foreign/multinational produced medicines. 
Conclusions: An assessment of the existing theoretical and empirical literature examining the link between “local production” of 
pharmaceuticals and medical devices and increased local access to these products reveals a paucity of literature explicitly dealing 
with this issue. Of the literature that does exist, methods used to date are insufficient to prove a robust relationship between local 
production of medical products and access to these products. There are mixed messages from various studies, and although the studies 
may correctly depict specific situations in specific countries with reference to specific products, such evidence cannot be generalized. 
Our review strongly supports the need for further research in understanding the dynamic link between local production and access to 
medical products 
Keywords: Pharmaceutical Policy, Industrial Policy, Access to Medicines, Pharmaceuticals. 
be desirable for low and middle income countries (LMICs)1. 
Clearly, countries such as India, Brazil, and others have proven 
that this is possible for medicines2-6. It is not clear whether it 
is possible for other LMICs to successfully repeat these efforts 
due to the need for major investments in human resources, 
financing and infrastructure to support innovation. 
Introduction 
Local production (LP) of essential medical technologies is at the 
interface of industrial/economic development policy and public 
health policy. From an industrial policy perspective, generating 
assured quality products by having a competitive pharmaceutical/
medical device industry with sufficient economies of scale would 52 Southern Med Review Vol 4  Issue 2  December 2011
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This question has been receiving much high-level attention   
in recent years with work funded by various governmental and 
non-governmental agencies including the United Kingdom (UK) 
Department for International Development- DFID7, the American 
Enterprise Institute8, the German Development Institute9, 
the World Bank1,10, Deutsche Gesellschaft für Internationale 
Zusammenarbeit GmbH, GIZ11-14, the African Union15 and the 
Southern Africa Development Council16. 
We further note the Global Strategy and Plan of Action on   
Public Health, Innovation and Intellectual Property (GSPA-PHI)   
of the World Health Organization (WHO) that includes a 
mandate to support development cooperation, partnerships, 
and networks to build and improve transfer of technology related 
to health innovation17. The WHO, in partnership with the United 
Nations Conference on Trade and Development (UNCTAD) and 
the International Centre for Trade and Sustainable Development 
(ICTSD), and with funding by the European Union (EU), is 
undertaking a project on improving access to medical products 
in developing countries through local production and related 
technology transfer18. 
From a public health perspective, understanding how changes 
in LP capacity will impact access to medical products is of great 
significance. We pose this as a question: “Does local production 
of medical products have beneficial impact on the resulting 
access to these products?” Such beneficial impact might, in 
principle, manifest itself as greater availability and/or lower 
prices for locally produced products, as opposed to imported 
products.
In this paper, we present results of a systematic literature 
review, summarizing existing theoretical and empirical work 
on LP of pharmaceutical products in LMICs, and its potential 
impact on access to medicines in LMICs. We assess to what 
extent the linkages between LP and access to medical products 
are explored in such studies; critically analyze whether the 
methods employed in the literature are sufficient to suggest a 
robust relationship between local production and access; and 
evaluate whether results obtained could be directly applied to 
local production conditions in developing and least developed 
country contexts.
Methodology
What do we mean by “local production”?
It is important to define what we understand by the term local 
production. Some “local” manufacturers are subsidiaries of 
multinational corporations (MNCs) and some are locally owned 
small-scale manufacturers serving a portion of the domestic 
market19. We use a jurisdictional, not an ownership definition. 
If production takes place in-country to produce biomedical 
products, this is “local production”. For pharmaceuticals, 
“production” can be primary (manufacture of active 
pharmaceutical ingredients (APIs) and intermediates from basic 
substances), secondary (production of finished dosage forms 
from raw materials and excipients or tertiary (packaging and 
labelling finished products or repackaging finished products). 
For vaccines, technology is specific for each inactivated or 
live attenuated vaccine product and may include isolating 
viral particles, producing “seed” viruses, bulk manufacture, 
and assembling polyvalent vaccines. For medical devices, the 
“device” component can be simple to complex, e.g. a bed to a 
Magnetic Resonance Imagery (MRI) machine20. 
What are “low- and middle- income” countries?
United Nations categorizations provide no established 
convention for the designation of “developed” and 
“developing” countries. The World Bank classifies countries 
according to income and this does not necessarily reflect 
development status. Significantly, all the World Bank low- and 
middle-income countries are considered to be “developing” 
under the United Nations classification. 
For this review, we classify LMICs according to the widely used 
World Bank system21 which divides countries according to 2009 
Gross National Income (GNI) per capita (calculated using the 
World Bank Atlas method): low income, $995 or less ; lower-
middle income, $996 – $3,945; upper-middle income, $3,946 
– $12,195. All other countries according to the World Bank 
scheme, are considered “developed”/high income countries 
(GNI per capita $12,196 or more. Middle-income countries such 
as Brazil, India, Mexico, South Africa and Taiwan have been 
called “emerging markets” using other classification systems.
What is “access to medicines”?
In the context of local production, “access” includes: (a) lower 
prices (thus greater affordability); (b) greater availability through 
the presence of locally made products and local distribution 
networks. In principle, these penetrate rural markets better 
than MNC produced products; (c) local adaptation of existing 
products by local firms through incremental innovation efforts; 
(d) new forms of innovative medicines and products developed 
locally and tailored to the local population(s).
Search strategies 
The primary objective of this review was to identify operational 
or implementation/analytical studies identifying empirically 
robust links between LP and access to biomedical products 
in LMICs. The kind of robust evidence that would satisfy our 
primary objectives can be summarized in Table 1. 
We based our literature search strategy on a single working 
hypothesis: studies showing a robust relationship between LP 
and access to medical products are sparse or even non-existent. 
Issues related to local production of medical products are often 
unlikely to be labelled as such, since “local production” is not a 
common term in academic research. Because of its cross-cutting 
nature, the “local production” literature is likely scattered 
in writings on innovation capacity, science and technology, 
industrial and pharmaceutical policy, intellectual property 
analysis and sometimes, health economics. 53 Southern Med Review Vol 4  Issue 2  December 2011
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Table 1. Criteria for robust evidence regarding LP and 
access
Criteria Explanation
Study objective
Define the relationship between LP and ‘access’ to 
biomedical products (medicines and/or diagnostics)
Study design
Interrupted time series analysis, and/or
Repeated measures studies, and/or
Controlled or uncontrolled before (-LP) and after (+LP) 
studies and/or
One-time descriptive comparisons of local and foreign-
made products.
Study sites
Low and middle income countries
Public and/or private health care institutions and/or 
pharmaceutical retail sector and/or public or private 
biomedical manufacturing site(s)
Preferred Study 
outcomes
Demonstrating a causal or strongly inferential link 
between LP of a medical product and improved/modified/
enhanced access to that product
We carried out a literature search using key words and their 
synonyms, “local, national, regional, domestic” and “production, 
manufacturing” and “pharmaceutical, medicine, diagnostic” in 
various combinations and searched in the title and/or abstract. 
Each database, however, has a unique set of keywords and 
search terms. This is why the search terms vary among the 
various databases, although the overall strategy remains the 
same (See Appendix 1). Specifically, MeSH terms were used for 
PUBMED and major subject headings used for EMBASE, CSA/
PAIS, and POPLINE. The search strategies were meant to capture 
both “high income” countries (e.g., U.S., Europe, Canada, 
Japan, New Zealand, Australia and the like) and “low- and 
middle- income” countries. In addition, there is a large amount 
of literature comparing MNCs and local producers in various 
countries with regard to finances, Foreign Direct Investment 
(FDI), and labour productivity that spans across sectors. “Local 
production” is not an economic term, so a further search 
was done for literature on comparative economics between 
domestic and foreign manufacturers in terms of business 
performance. The databases were searched using combinations 
of terms such as “comparison, foreign, multinational, domestic, 
local, performance, price, pharmaceutical, emerging market”. 
PUBMED search terms are in Appendix 1.
The specific databases used were: AfricaWide Information, 
PUBMED (including the “Health Services” Subcategory, CINAHL, 
EMBASE, Thomson Reuters (formerly ISI) Web of Science, 
EconLit, CSA International Bibliography of Social Science, 
International Network of Rational Use of Medicines (INRUD), 
PAIS International, POPLINE (One Source), and Google Scholar®. 
References from PUBMED (including the “Health Services” 
Subcategory, CINAHL, EMBASE, Thomson Reuters (formerly 
ISI) Web of Science, EconLit, CSA International Bibliography 
of Social Science, PAIS International, and POPLINE were placed 
in EndNote® bibliographic software files. We reviewed these 
EndNote® files and searched within all articles with abstracts for 
terms “local, national, regional, domestic” and “production, 
manufacturing” and “pharmaceutical, medicine, diagnostic” in 
various combinations. We read each of the resulting abstracts or 
full-length articles (if available) and then applied the “screening” 
criteria of Table 1.
To search for so-called gray literature, we reviewed the following 
websites and any associated databases for literature dealing 
with both local production and access: OECD, the World Bank, 
the World Health Organization (WHO), Pan American Health 
Organization (PAHO), the Medicines Transparency Alliance 
(MeTA), UNIDO/GTZ, UNDP, LEXISNEXIS, e-medicine archives, 
Google®, Google Scholar®. We then applied the “screening” 
criteria of Table 1 to the result.
For the Google® searches, we also looked for specific countries: 
Argentina, Ghana, Nigeria, Brazil, Egypt, Jordan, South Africa, 
Thailand, Bangladesh, Philippines, Tanzania, Mexico, and 
India. We reviewed all articles up to the first 20 “hits”. The 
most relevant of the first 20 articles (based on whether it was 
concerned with both local production and access) were then 
searched for all hyperlinked “related articles”. We repeated this 
search twice, once for “medicines” and again for “diagnostics” 
(See Appendix 2). For all Google® based searches that were not 
country specific, the total number of initial “hits” was enormous 
so we limited ourselves to reviewing the first 100 references and 
applied the screening criteria of Table 1. 
Results 
We found a total of 154 relevant references and based on the 
Table 1 screening tool, we narrowed this down to a total of 
20 (See Tables 2-4). See Appendix 1 and Appendix 2 for more 
information on search terms for these references. 
We have identified two themes of the literature that are relevant: 
1.   The business and economics literature on the comparative 
economics and strategic planning of multinational and 
domestic firms. Of this literature, there are few references on 
emerging markets or LMICs and even fewer with regard to 
comparing local and MNC pharmaceutical producers.
2.   The sparse and descriptive literature on the benefits of local 
production. 
Theme 1: Comparing the “behavior” 
of domestic and foreign producers 
(MNCs) in-country
There is an extensive literature showing that MNCs and local firms 
are different, based on the fact that MNCs are relatively more 
intensive in research and development (R&D) and advertising 
assets than non-MNCs22-25. The theoretical literature attempts 
to explain the existence of MNCs in foreign markets when they 
are at a disadvantage relative to local firms with respect to 
knowledge of domestic markets. Theories focus on explaining 54 Southern Med Review Vol 4  Issue 2  December 2011
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how MNCs overcome these disadvantages by possessing 
proprietary, knowledge-based and generally intangible assets 
related to production techniques and processes, marketing 
networks and/or management ability. 
We have identified literature on the comparative behavior of 
MNCs and local pharmaceutical and chemical producers (Table 
2). The study on India is not directed at “access” specifically but 
at structural and functional properties of domestic firms versus 
MNCs27. The comparative study on Bangladesh asserts that local 
producers have a distinct cost advantage over MNCs but there 
is no data in the paper to support this28.
Theme 2: Benefits of local production 
of medical products: 
Competitive costing. In principle, a dedicated local production 
facility could be competitive against the lowest cost international 
producers on the basis of improved process technology, 
continuous (as opposed to batch) processing, and better 
economies of scale. The extent of the cost saving depends on 
which products are being manufactured and what processing 
steps are required. Table 3 summarizes the evidence gathered 
from our review on this topic. 
Figure 1 (opposite) is adapted from Table 1 of reference 33. The 
solid dark blue bars show the average price of the listed foreign-
produced generic medicines ($ per pill: Y axis) of Germany, 
Cyprus, India, Canada, Italy, and the bars to their right are 
the average price ($ per pill: Y axis) of the Malaysian generic 
counterpart. The light blue bars are the percentage (x100) 
difference in price between the foreign and locally-produced 
generics. The foreign generic version was more expensive 
than the locally-produced generic version in just 4 of the 10 
medicines (glicazide 60 mg, ticlopidine 250 mg, ranitidine 150 
mg and cetirizine 10mg). The locally-produced generic versions 
of atenolol, loratidine and amoxicillin were significantly more 
expensive than the foreign-produced versions. 
Reliability of supply. Local production in-country would 
improve security of supply and extend procurement options, 
Country
Analytical 
Method
Conclusion(s) Reference
Turkey Surveys Comparison of the product structure of MNCs and that of local firms. No significant difference between them 
in terms of the products that they produce and market. The author could NOT conclude that the presence of 
local firms in the Turkish pharmaceutical industry had been beneficial because; “...all the negative aspects of 
pharmaceutical production and exchange which the critics have attributed solely to MNCs have been similarly 
reproduced by local firms in the pharmaceutical industry in Turkey. “ Local firms and MNCs were equally involved 
in overpricing activities.  The available evidence indicated that MNCs overpriced to an even higher extent than 
local firms.  
(26)
India Firm-level data 
from National 
Statistics Office: 
Econometric study
Domestic firms, most of which are controlled by family based structures, enjoy higher efficiencies (operating profit 
margins, net profit margins, fixed asset turnover, working capital,  inventory holding period, and  many others) 
than affiliates of MNCs
(27) 
Bangladesh Stock exchange 
data/Econometric 
study
Domestic production’s cost advantage over large MNCs gives local products a price advantage.  MNCs have more 
advantageous infrastructures, technology, finances and administration
(28) 
Table 2. Summary of literature on comparative behavior of MNCs and local pharmaceutical/chemical producers
0
-1
-0.5
0.5
1
1.5
2.5
2
Foreign Produced ($ per pill)
Locally Produced ($ per pill)
% difference (x100)
G
l
i
c
a
z
i
d
e
 
6
0
m
g
 
t
a
b
T
i
c
l
o
p
i
d
i
n
e
,
 
2
5
0
 
m
g
 
t
a
b
G
l
i
b
e
n
c
l
a
m
i
d
e
,
 
5
m
g
 
t
a
b
A
t
e
n
o
l
o
l
,
 
5
0
m
g
R
a
n
i
t
i
d
i
n
e
,
 
1
5
0
 
m
g
 
t
a
b
 
D
i
c
l
o
f
e
n
a
c
 
N
a
,
 
5
0
m
g
 
t
a
b
E
n
a
l
p
r
i
l
,
 
2
0
m
g
 
t
a
b
A
m
o
x
i
c
i
l
l
i
n
,
 
5
0
0
m
g
 
c
a
p
C
e
t
r
i
z
i
n
e
,
 
1
0
m
g
 
t
a
b
L
o
r
a
t
i
d
i
n
e
,
 
1
0
m
g
 
t
a
b
Notes: % difference in price between foreign (F) and local producer (LP) = 
(difference in price between the average of the F prices and the average of the 
LP prices)/ average value of the all F and LP prices combined) X 100. 
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Country
Analytical 
Method
Conclusion(s) Reference
Tanzania Survey Nearly half (46%) of various tracer medicines were locally made; only injectable, some chronic illness 
medicines, and one antibiotic were solely available as imports.  No significant differences existed between 
prices of medicines from the three main countries of origin (India, Kenya, Tanzania),  suggesting  competitive 
pricing with no apparent advantage given to the Tanzanian products
(29) (39) 
Tanzania Survey Local production supplies approximately 30% of private and public markets. Various “tracer medicines” 
were widely available in shops and non-government facilities. Of these medicines, 66% were locally made 
(compare the 46% figure cited above by ref. 30) and “…few significant price differentials by country of 
origin for the most widely distributed medicines among … tracer drugs”.  
(30)
Brazil Time series As of 2006, prices for Brazil’s locally produced generics were generally much higher than corresponding 
global prices. These prices have risen in Brazil while declining globally. The estimated “excess” costs of 
Brazil’s locally produced generics totaled US$110 million from 2001 to 2005.
(31)
Various sub-
Saharan African 
countries
Economic 
modeling
Domestic production of a variety of medicines may have a “modest” impact on medicine affordability.  
“Modest”, defined as between a 1-26% reduction in ex works price.  This price reduction was found to be 
very sensitive to increase in API prices or a loss of (or failure to reach) market share and this could “easily” 
negate price reductions.
(7)
India Economic 
modelingi  
“Significant” additional expenditure that the representative Indian consumer would need to incur in the face 
of the domestic product withdrawal(s) and assumed to be an impact on “access” due to “ …differences 
in the marketing and distribution networks, domestic products being  more readily available to Indian 
consumers than products produced by foreign subsidiaries.”  In absolute terms, without any price regulation, 
the prices of foreign patented products would rise between 100% and 400% when local production ceased.
(32)
Malaysia Survey  Some local generics were more expensive than imported generic medicines.  Retail markups for both were 
assumed identical and local producers may not be “efficiently producing affordable medicines” and are 
passing the high costs on to the consumer (See Figure 1, below).
(33)
Bangladesh Survey Pricing differentiation of 35 essential medicines between local producers and multinational pharmaceutical 
companies showed that only two products (Aspirin 300 mg, Chlorpromazine 25 mg) out of 35 essential 
medicine products had locally-produced unit prices higher than the corresponding MNC products. The prices 
of various locally produced dosages of ibuprofen and paracetamol were only slightly less than the MNC 
versions. The majority of locally produced anti-infectives were less expensive than their MNC counterparts.  
Five essential medicine products for chronic conditions (Atenolol 50 mg, Glibenclamide, Amitriptyline, 
Griseofulvin and Salbutamol) had exactly the same prices for locally produced and MNC-produced.  
(34)
Vietnam Survey Locally produced HIV/AIDS medicines l (anti-retrovirals: ARVs) are priced considerably lower than imported 
ARVs currently on the Vietnamese market, but they are five to seven times higher than the current best offer 
on the international market. 
(35)
Vietnam Survey Locally produced drugs are “less expensive than those imported from the West, Malaysia and Thailand” but 
this statement is not supported by any data.
(36)
Palestine Survey Although only at a single Palestinian pharmacy, locally produced pharmaceuticals were significantly cheaper 
than their foreign counterparts.
(37)
Palestine Survey Analysis of 34 single and 6 combination antibiotic preparations of  local and foreign firms (including 
those marketed by Israel) showed that in all cases the “… price difference was in favor of the locally 
manufactured products, as all the prices of local antibiotics are less than imported ones.” (no data 
presented)
(38)
iThe basic counterfactual scenarios all involve the withdrawal of one or more of the locally produced product groups from the market in the face of 
patent protection. The idea is that if patents for, e.g., ciprofloxacin, had been recognized in India, not all domestic products containing ciprofloxacin 
would be present in the market. That would leave only the foreign ciprofloxacin product group in the market.
Table 3. Summary of literature on cost of locally produced and imported medicines
although proving this empirically would be difficult. In Tanzania, 
the government procurement agency obtains supplies through 
one large annual tender39 . (See Table 4)
Improved quality standards. In principle, local production 
with regular surveillance on quality control issues in conjunction 
with health authorities could lead to improved quality standards 
without compromising on cost (See Table 4).
Foreign import savings. Local production may, to an extent, 
offset the very large import deficit and foreign exchange 
exposure that is almost inevitable for some medicines that are 56 Southern Med Review Vol 4  Issue 2  December 2011
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produced primarily by MNCs (e.g., ARVs). We could find no 
literature fitting our criteria to support this for LMICs.
Development of further innovation capacity. Many policy 
makers in LMICs have competed rigorously in attracting 
foreign direct investment (FDI). A common justification for 
this incentive-based competition is the argument that FDI 
provides not only capital and additional employment but also 
new knowledge to recipient economies. In LMICs, dependence 
on foreign production explains the large number of studies 
emphasizing the importance of accessing and absorbing 
international knowledge for acquiring competitiveness and 
fostering economic growth in these countries, and in particular 
the important role that international knowledge spillovers could 
play in that process. The literature is vast44. See Table 4 for the 
evidence supporting the role of local production as a means of 
furthering innovation in medical products.
Creation of enhanced export capacity. In principle, a local 
producer could also become a significant exporter. Although the 
Table 4. Summary of literature on presumed benefits of local production of medical products
Potential 
Benefit of LP
Country
Analytical 
Method
Conclusion(s) Reference
Reliable supply Tanzania Survey In Tanzania, there are several competing supply chains:  1.   Delivery chain of mostly ARV 
and Tuberculosis (TB) medicines from only international firms to facilities treating free at 
point of use. 
2.  Supply chain from local firms and Indian importers to public/NGO facilities for out-of-
pocket payment.
3.  Private market without a controlled supply chain, selling both subsidized imports and 
local and imported commercial supplies.  The ARV/TB supply chain excludes local suppliers. 
The supply chain for public/NGO facilities tends to encourage local suppliers, and could 
lead to “...upgrading of local industrial capabilities and employment”, although the 
validity of this assertion was not analyzed.
(40)
Improved quality 
standards
Seven African 
countries
Survey/chemical 
analyses of a  
pilot study to 
assess the quality 
of chloroquine 
syrup (CQS) or 
tablets (CQT)
There were quality failures of 56% (27/48) among locally made products, compared to 
47.2% (17/36) for foreign products for CQT active ingredient content, and 28% (7/25) 
versus 13% (3/23) for CQS active ingredient content.
(41)
Kenya Cross-sectional 
laboratory 
analysis and  
survey of 
pharmaceutical 
companies in 
Nairobi
Private pharmacies stocked few of the locally manufactured products due to “low 
doctor and/or patient acceptance.” Varying factors contributed to poor availability and 
acceptability of some locally manufactured products in Kenya.
(42)
Developing 
innovation 
capacity
Uganda Survey; case 
studies
Ugandan pharmaceutical companies upgraded their technology by a combination of 
upstream vertical linkages to suppliers, their existing linkages downstream in the chain 
as importers and retailers of pharmaceuticals for the domestic market, and by the 
government policies.  The Ugandan companies have upgraded by importing finished 
technologies and knowledge, not by learning production methods.  Production is at a low 
level technologically and has not increased the companies’ technological capabilities. 
(43) 
Developing 
human capital
Tanzania Survey of a single 
company whose 
staff comprised 
mainly of Indian 
and British 
expatriates
Tanzanian staff was in the minority and that this was “... a major problem.”   The company 
would prefer to employ Tanzanian staff, but the competency needed for pharmaceutical 
production is simply not available in the country. In total the company employs 800 people 
in Tanzania. The Tanzanian employees are unskilled and work in the packaging area, 
whereas the Indian and British staff is skilled.
(12) 
initial intention of a ‘local producer” is most likely to develop as 
a local supplier of a highly strategic or niche product, ultimately 
this could assist in building a regional production capacity 
which would benefit, for instance, the entire African continent. 
From a macroeconomic view, this may help improve any trade 
imbalance. But this will also depend on the products themselves, 
their patent cover and the scope of any voluntary license 
agreements which may cover patented products. We found no 
direct evidence fitting our criteria to support the link between 
LP and increased exports e.g. Sub-Saharan Africa (see Table 1).
Development of human capital. Most of the essential skills for 
a successful biomedicine manufacturing sector may already be 
well developed in certain countries (e.g., India, Thailand, South 
Africa) within academic institutions (organic chemistry, chemical 
engineering, mechanical engineering, pharmacology, etc). At 
the same time, it may be that experienced local professionals 
with knowledge of pharmaceutical manufacturing within an 
industrial environment are very limited (See Table 4).57 Southern Med Review Vol 4  Issue 2  December 2011
Local production of medical technologies
Discussion 
Absence of evidence is not evidence of absence. There are 
surely observable links between local production and access to 
medical products in LMICs. We infer from the literature that 
the link between local production and price, if such a link 
exists, should be observable and measurable. Further, the link   
between local production and accessibility should be similarly 
observable. Nonetheless, we have not seen rigorous evidence 
for either of these links in the literature we have reviewed. In 
short, the direct evidence in LMICs is too weak to answer the 
question of whether or not local production of medical products 
has a salutary effect on the resulting access to these products. 
There is a preponderance of case studies and descriptive surveys. 
Two key points emerge from this work.
•   The vast majority of pricing surveys observed do not distinguish 
the price of “local” versus “foreign” producers on a product-
by-product basis. An important first step in development of 
this literature would be if even a few of the comprehensive 
analyses of price, accessibility and affordability performed by 
the WHO and Health Action International (HAI) were repeated 
using distinctions between local- and foreign-made identical 
products45-49 .
•   There is an almost complete absence of rigorous information 
on the link between LP and access to medical devices. Modern 
technology is producing an abundance of medical devices at a 
rate that soon makes the latest device obsolete. Furthermore, 
there is an extreme diversity in the medical device arena in 
terms of types of devices, degrees of complexity, applications, 
usage, users and categories. Just as with pharmaceuticals, 
research in medical devices can be mismatched with actual 
public health needs. Furthermore, almost all medical devices 
present in developing countries have been designed for use in 
industrialized countries. Whether or not local production of 
medical devices can contribute to improved access to devices 
is an open question.
In retrospect, there are several reasonable explanations for 
the apparent lack of published evidence in general. First and 
foremost, many of the complexities of investigating the link 
between LP and access to medical products are simply not 
susceptible to formal academic analysis. For the most part in 
many LMICs, relevant data sets are limited and are of doubtful 
quality10. While there is excellent long term data primarily 
compiled by international pharmaceutical market research audit 
companies, beyond the OECD such data is sparse10. 
Second, the relationship between LP and access to medical 
products is extremely dynamic. The literature provides a 
retrospective view but the business of developing policy, of 
technology transfer and of manufacturing a product for market 
will not wait for academicsi.. The most useful information may 
indeed be available directly in-country and in real time.
Third, notwithstanding some national policies in LMICs that 
support local production, “access to medicines” is not the 
primary reason for building a local factory. At present, the 
business and industry pressures to build a local producer in 
an LMIC will still render health policy concerns of secondary 
importance. It could be that links between LP and access 
have not been explored because it is harder to make access a 
particular concern for an individual firm, and at the collective 
level, accountability is hard to enforce (since it cannot be broken 
up for each and every firm)ii.
We cannot state unequivocally that the references found here 
are the only potentially useful and reliable sources of information 
on this subject. Although we attempted to create a systematic 
search strategy, one could certainly find additional documents 
using a less efficient free form search. It is almost certainly true 
that this search strategy has not covered the entire literature, 
given its cross-cutting nature. However, what is presented here 
covers sufficient ground to serve as a starting point. In our view, 
we can say with confidence that while some details have been 
missed in our search strategy, overall, this is the general sense of 
the literature at the present time. 
Going further, if we are going create a more robust evidentiary 
framework for the linkage between LP and “access”, we need 
better monitoring and evaluation. In principle, it is possible 
to create longitudinal data or cross-sectional time series data, 
where the same subjects (e.g., several local and MNC producers) 
are observed at multiple time periods. One can imagine a 
nationally representative sample of local producers and /or 
MNC subsidiaries and/or a sample of pharmacies, clinics and the 
like, each member of the panel being surveyed repeatedly over 
multiple years for various phenomena. Realistically, there is likely 
to be very poor access to firm- and/or plant-level data. The lack 
of good data may make it impossible to sort out the various 
influences that are involved over time. For example, one might 
observe in a region dominated by local producers a time series 
that shows higher prices than an adjacent “control” region 
dominated by MNC producers, this may result from the fact 
that foreign MNCs are more capital and technology intensive 
and that this price difference would disappear if differences in 
capital intensity could be controlled for. 
An interrupted time series may be useful in studying the 
linkage between LP and access50-51. In this analysis, the effect 
of an intervention on an outcome variable can assume a variety 
of forms over time. In this case, the intervention is made by 
someone other than the researcher and it is not normally made 
for experimental purposes and would be considered a natural 
experiment. If available, one creates a time series beginning 
i. The dynamic nature of this can be illustrated by the United States. Medicine shortages in the United States have been growing in number, driven by 
many factors such as shortage of raw materials, manufacturing delays, business decisions to manufacture another product, a tendency by hospitals 
and wholesalers to order medicines on demand rather than stockpile supplies52, 53.
ii We note, however, the Access to Medicines Index (http://www.accesstomedicineindex.org/) which ranks 27 MNCs, comprising 20 originators and 
seven generics manufacturers. The ranking is based on 106 indicators that measure activities across four strategic and seven technical areas, including 
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from well before the intervention and continuing through and 
after it. For instance, prior to, during, and after a major financial 
investment and/or a policy change and/or a new factory going 
“on line”, one could look at: 1. product-by-product price 
comparisons of various local vs. MNC products; or 2. market 
share surveys of availability of local vs. MNC-produced generics/ 
brand names on a product-by-product basis from the same sites; 
or 3. repeated surveys of patterns of medicine distribution of 
a suite of local producers vs. importers/in-country MNCs . The 
limiting factors are again the existence of data on medicine 
production, or price or access/affordability, volume market share 
and the like.
Conclusions 
This appears to be the first such review of the literature that 
attempts to answer the question regarding the kinds of evidence 
linking LP and access to medical products. Our conclusions 
appear to support our preliminary working hypothesis that 
studies showing a robust relationship between LP and access to 
medical products are sparse at best. 
Although “local production” is being actively pursued in many 
LMICs, the link between local production and access to medical 
products remains implicit in most cases. The extent to which 
local production for medical products and new investments 
in this area in developing countries are aligned with those 
countries’ public health needs is an important question and 
requires close examination and policy attention. Even if such 
policies are aligned, how can the link between local production 
and access to medicines be supported by good evidence? In 
this regard, we hope that this document contributes towards 
beginning an evidence-base linking industrial and health policy.
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Database(s) Search term key words for database(s)
Number of initial 
“hits”
Number relevant
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“screening”
LEXIS NEXIS Local, production, pharmaceutical, medicine diagnostic 997  0 0
GOOGLE®/GOOGLE SCHOLAR® Local, innovation, pharmaceutical, medicine, diagnostic, access 1000 51 0
AfricaWide Information 
CINAHL
Local production pharmaceutical, medicine diagnostic 0
0
OECD
PUBMED
HEALTH SERVICES SUBSET OF PUBMED
Local production
Drug Industry {MeSH} AND Medicine {MeSH}
Local production
68
2057
4
0
26
0
0
0
0
POPLINE
ECONLIT
ECONLIT
medicine / pharmac* / diagnostic & production / manufacture
medicine / pharmac* / diagnostic & production / manufacture
Comparative AND (foreign OR multinational) AND (domestic OR 
local) AND performance OR price AND “pharmaceutical”
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1127
3
9
27
0
3
6
CSA
ISI Web of Knowledge
CSA
Local production pharmaceutical medicine diagnostic
Local production pharmaceutical medicine diagnostic
Comparative AND (foreign OR multinational) AND (domestic OR 
local) AND performance OR price
Same as immediately above AND “pharmaceutical” 
13
429
818
38
3
8
13
0
2
3
Appendix 1: Search terms used for 
databases and number of references 
identified
The search terms for PUBMED were as follows: 
1.    (domestic[All Fields] AND (“economics”[MeSH Terms] OR 
“economics”[All Fields] OR “production”[All Fields])) AND 
(“pharmacy”[MeSH Terms] OR “pharmacy”[All Fields] OR 
“pharmaceutical”[All Fields] OR “dosage forms”[MeSH 
Terms] OR (“dosage”[All Fields] AND “forms”[All Fields]) OR 
“dosage forms”[All Fields]) 
2.   “medicine industry”[Mesh] AND “medicine”[Mesh]
3.    (Medicine[ti] OR Pharmaceutical[ti] OR Diagnostic[ti] OR 
“Medicines, Essential/supply and distribution”[MAJR]) 
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4.   Limits – Humans 
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Appendix 2: Search term used for 
Google Scholar® country specific 
searches
Database Search term key words for database(s)
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SCHOLAR® 
COUNTRY 
SPECIFIC
I. Specific country AND pharmaceutical
AND 
with the exact phrase: “production”
AND 
with at least one of these words: “local domestic national 
regional diagnostic”
II. Specific country AND diagnostic
AND 
with the exact phrase: “production”
AND 
with at least one of the words: “local domestic national 
regional pharmaceutical”
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“hits”
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Number after 
“screening”
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